Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Dec 22, 2023 (filed on Dec 28, 2023)Insider Name:Portnoy Mark L.Ownership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:25,000Price:$6.47
-
Dec 22, 2023 (filed on Dec 28, 2023)Insider Name:Mikulinsky OlegOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10,000Price:$5.88
-
Dec 22, 2023 (filed on Dec 28, 2023)Insider Name:Taymans Jill MOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10,000Price:$5.88
-
Dec 22, 2023 (filed on Dec 28, 2023)Insider Name:Portnoy DavidOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:50,000Price:$6.47
-
Oct 10, 2023 (filed on Oct 12, 2023)Insider Name:Berger Harold D.Ownership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,300Price:$4.90
Filings by filing date
-
Dec 22, 2023 (filed on Dec 28, 2023)Insider Name:Portnoy Mark L.Ownership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:25,000Price:$6.47
-
Dec 22, 2023 (filed on Dec 28, 2023)Insider Name:Mikulinsky OlegOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10,000Price:$5.88
-
Dec 22, 2023 (filed on Dec 28, 2023)Insider Name:Taymans Jill MOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10,000Price:$5.88
-
Dec 22, 2023 (filed on Dec 28, 2023)Insider Name:Portnoy DavidOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:50,000Price:$6.47
-
Oct 10, 2023 (filed on Oct 12, 2023)Insider Name:Berger Harold D.Ownership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,300Price:$4.90
News
Biz Brief
Sector: Healthcare | Industry: Healthcare Facilities & Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 700 BROOKER CREEK BLVD, SUITE 1800 OLDSMAR FL 34677 |
Tel: | 1-813-7492102 |
Website: | https://www.cryo-cell.com |
IR: | See website |
Key People | ||
David I. Portnoy Chairman of the Board, Co-Chief Executive Officer | Mark L. Portnoy Co-Chief Executive Officer, Director | Jill M. Taymans Chief Financial Officer, Vice President - Finance |
Oleg Mikulinsky Chief Information Officer | Joanne Kurtzberg Medical Director |
Business Overview |
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. |
Financial Overview |
For the three months ended 29 February 2024, CRYO-CELL International, Inc. revenues increased less than 1% to $7.9M. Net income decreased 27% to $556K. Revenues reflect Umbilical cord blood and cord tissue stem cell service segment increase of 3% to $7.8M, also reflect Public cord blood banking segment decrease of 81% to $44K, Prepacyte CB segment decrease of 91% to $3K. |
Employees: | 82 as of Nov 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $70.80M as of Feb 29, 2024 |
Annual revenue (TTM): | $31.37M as of Feb 29, 2024 |
EBITDA (TTM): | $4.80M as of Feb 29, 2024 |
Net annual income (TTM): | -$9.73M as of Feb 29, 2024 |
Free cash flow (TTM): | -$0.00M as of Feb 29, 2024 |
Net Debt Last Fiscal Year: | $7.58M as of Feb 29, 2024 |
Shares outstanding: | 8,104,477 as of Apr 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |